Krystal Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	389.13	290.52	50.7	-	-
Revenue Growth (YoY)	33.95%	473.02%	-	-	-
Cost of Revenue	23.05	20.06	3.09	-	-
Gross Profit	366.08	270.45	47.61	-	-
Selling, General & Admin	146.74	113.63	98.29	78.84	41.99
Research & Development	58.05	53.58	46.43	42.46	27.88
Operating Expenses	204.79	167.21	144.72	121.3	69.88
Operating Income	161.3	103.25	-97.12	-121.3	-69.88
Interest Expense	-	-	-	-	-1.49
Interest & Investment Income	28.18	29.61	22.51	5.22	0.2
EBT Excluding Unusual Items	189.47	132.86	-74.6	-116.08	-71.17
Gain (Loss) on Sale of Assets	-	-	100	-	-
Legal Settlements	-	-37.5	-12.5	-25	-
Pretax Income	189.47	95.36	12.9	-139.98	-69.57
Income Tax Expense	-15.36	6.2	1.97	-	-
Net Income	204.83	89.16	10.93	-139.98	-69.57
Net Income to Common	204.83	89.16	10.93	-139.98	-69.57
Net Income Growth	129.74%	715.58%	-	-	-
Shares Outstanding (Basic)	29	29	27	25	22
Shares Outstanding (Diluted)	30	30	28	25	22
Shares Change (YoY)	0.71%	7.16%	8.87%	14.85%	18.15%
EPS (Basic)	7.08	3.12	0.40	-5.49	-3.13
EPS (Diluted)	6.84	3.00	0.39	-5.49	-3.13
EPS Growth	128.00%	669.23%	-	-	-
Free Cash Flow	188.91	119.18	-100.6	-153.55	-116.27
Free Cash Flow Per Share	6.31	4.01	-3.63	-6.02	-5.24
Gross Margin	94.08%	93.09%	93.90%	-	-
Operating Margin	41.45%	35.54%	-191.56%	-	-
Profit Margin	52.64%	30.69%	21.56%	-	-
Free Cash Flow Margin	48.55%	41.02%	-198.43%	-	-
EBITDA	162.92	105.72	-93.21	-118.65	-67.11
EBITDA Margin	41.87%	36.39%	-183.85%	-	-
D&A For EBITDA	1.62	2.47	3.91	2.64	2.77
EBIT	161.3	103.25	-97.12	-121.3	-69.88
EBIT Margin	41.45%	35.54%	-191.56%	-	-
Effective Tax Rate	-	6.50%	15.24%	-	-

Updated Feb 17, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q